§ 522.1881 Sterile prednisolone acetate aqueous suspension.

- (a) *Specifications*. Each milliliter of sterile aqueous suspension contains 25 milligrams of prednisolone acetate.
- (b) Sponsor. See No. 000061 in §510.600(c) of this chapter.
- (c) NAS/NRC status. The conditions of use are NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified in §514.111 of this chapter but may require bioequivalency and safety information.
- (d) Conditions of use. (1) The drug is indicated in the treatment of dogs, cats, and horses for conditions requiring an anti-inflammatory agent. The drug is indicated for the treatment of acute musculoskeletal inflammations such as bursitis, carpitis, and spondylitis. The drug is indicated as supportive therapy in nonspecific dermatosis such as summer eczema and atopy. The drug may be used as supportive therapy pre- and post-operatively and for various stress conditions when corticosteroids are required while the animal is being treated for a specific condition.
- (2) The drug is administered to horses intra-articularly at a dosage level of 50 to 100 milligrams. The dose may be repeated when necessary. If no response is noted after 3 or 4 days, the possibility must be considered that the condition is unresponsive to prednisolone therapy. The drug is administered to dogs and cats intramuscularly at a dosage level of 10 to 50 milligrams. The dosage may be repeated when necessary. If the condition is of a chronic nature, an oral corticosteroid may be given as a maintenance dosage. The drug may be given intra-articularly to dogs and cats at a dosage level of 5 to 25 milligrams. The dose may be repeated when necessary after 7 days for two or three doses.
- (3) The labeling shall comply with the requirements of §510.410 of this chapter for corticosteroids.
- (4) Not for use in horses intended for food.
- (5) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[52 FR 23032, June 17, 1987]

§ 522.1883 Prednisolone sodium phosphate injection, sterile.

- (a)(1) Specifications. Each milliliter contains 20 milligrams of prednisolone sodium phosphate (equivalent to 14.88 milligrams of prednisolone) in sterile aqueous solution.
- (2) *Sponsor*. See No. 000864 in §510.600(c) of this chapter.
- (3) Conditions of use—(i) It is used in treatment of dogs when a rapid adrenal glucocorticoid and/or anti-inflammatory effect is necessary.¹
- (ii) It is administered intravenously in a dosage of 2½ to 5 milligrams of prednisolone sodium phosphate per pound of body weight, initially for shock and shock-like states, followed by equal maintenance doses at 1-, 3-, 6-, or 10-hour intervals as determined by the condition of the animal. If permanent use is required, oral therapy (tabnet) may be substituted. If therapy is to be withdrawn after prolonged use, reduce daily dose gradually over a number of days.
- (iii) Do not use in viral infections. Except in emergency therapy, do not use with tuberculosis, chronic nephritis, Cushing's disease, or peptic ulcers. With infections, use appropriate antibacterial therapy with, and for at least 3 days after, discontinuance of use and disappearance of all signs of infection.¹
- (iv) Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.
- (v) Federal law restricts this drug to use by or on the order of a licensed veterinarian. 1
- (b) [Reserved]

[43 FR 29769, July 11, 1978, as amended at 49 FR 23834, June 8, 1984]

§ 522.1884 Prednisolone sodium succinate injection.

- (a) Chemical name. 11 beta, 17, 21-Trihydroxypregna-1, 4-diene-3, 20-dione 21-succinate sodium salt.
- (b) Specifications. Each milliliter of prednisolone sodium succinate injection contains: Prednisolone sodium